{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T04:50:45Z","timestamp":1794631845374,"version":"4.9.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T00:00:00Z","timestamp":1581292800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T00:00:00Z","timestamp":1581292800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"DFG ImmunoSensation","award":["EXC 1023"],"award-info":[{"award-number":["EXC 1023"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Upregulation of the histone methyltransferase enzyme EZH2 and its histone modification H3K27me3 has been linked to melanoma progression, metastasis, and resistance to immune checkpoint blockade (ICB). In clinical trials, EZH2 inhibitors are currently tested to overcome resistance to ICB. The aim of this study is to evaluate expression patterns and the predictive value of H3K27me3 and EZH2 in metastatic melanoma samples prior to ICB. As H3K27me3 expression has been associated with a dedifferentiated, invasive melanoma phenotype, we also investigated the prognostic value of H3K27me3 expression in primary melanomas.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>H3K27me3 and EZH2 expression were evaluated in a cohort of 44 metastatic melanoma samples before ICB using immunohistochemistry (IHC). 29\/44 (66%) of melanomas showed H3K27me3 expression, and 6\/44 (14%) showed EZH2 expression. No predictive value for therapeutic response to anti-PD-1 therapy could be found for H3K27me3 or EZH2 expression on melanoma cells. To investigate the prognostic significance of H3K27me3, we analyzed H3K27me3 expression in a representative cohort of 136 primary melanomas with known sentinel lymph node status. H3K27me3 expression is associated with increased tumor thickness and nodal involvement. Melanoma metastases showed a higher expression of H3K27me3 in comparison to primary melanomas. In human melanoma cell lines, TNF\u03b1 and INF\u03b3 could not induce H3K27me3 expression.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Our study shows that H3K27me3 expression is more frequent than EZH2 and is associated with a more invasive and metastatic melanoma cell phenotype. We suggest that H3K27me3 expression by IHC might be a suitable method to evaluate the activity of EZH2 inhibitors in clinical trials.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13148-020-0818-7","type":"journal-article","created":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T18:03:10Z","timestamp":1581357790000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["H3K27me3 and EZH2 expression in melanoma: relevance for melanoma progression and response to immune checkpoint blockade"],"prefix":"10.1186","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4358-7377","authenticated-orcid":false,"given":"Friederike","family":"Hoffmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Niebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia","family":"Aymans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Ferring-Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimo","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Landsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,10]]},"reference":[{"issue":"2","key":"818_CR1","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.cell.2006.02.041","volume":"125","author":"BE Bernstein","year":"2006","unstructured":"Bernstein BE, Mikkelsen TS, Xie X, Kamal M, Huebert DJ, Cuff J, et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell. 2006;125(2):315\u201326.","journal-title":"Cell."},{"issue":"2","key":"818_CR2","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.neo.2016.01.003","volume":"18","author":"J Tiffen","year":"2016","unstructured":"Tiffen J, Wilson S, Gallagher SJ, Hersey P, Filipp FV. Somatic copy number amplification and hyperactivating somatic mutations of EZH2 correlate with dna methylation and drive epigenetic silencing of genes involved in tumor suppression and immune responses in melanoma. Neoplasia N Y N. 2016;18(2):121\u201332.","journal-title":"Neoplasia N Y N."},{"issue":"4","key":"818_CR3","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.celrep.2017.07.007","volume":"20","author":"D Zingg","year":"2017","unstructured":"Zingg D, Arenas-Ramirez N, Sahin D, Rosalia RA, Antunes AT, Haeusel J, et al. The histone methyltransferase Ezh2 controls mechanisms of adaptive resistance to tumor immunotherapy. Cell Rep. 2017;20(4):854\u201367.","journal-title":"Cell Rep"},{"issue":"7577","key":"818_CR4","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature15520","volume":"527","author":"D Peng","year":"2015","unstructured":"Peng D, Kryczek I, Nagarsheth N, Zhao L, Wei S, Wang W, et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature. 2015;527(7577):249\u201353.","journal-title":"Nature."},{"issue":"4","key":"818_CR5","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1158\/2159-8290.CD-18-1090","volume":"9","author":"D Ennishi","year":"2019","unstructured":"Ennishi D, Takata K, B\u00e9guelin W, Duns G, Mottok A, Farinha P, et al. Molecular and genetic characterization of mhc deficiency identifies EZH2 as therapeutic target for enhancing immune recognition. Cancer Discov. 2019;9(4):546\u201363.","journal-title":"Cancer Discov."},{"issue":"8","key":"818_CR6","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1038\/s41591-018-0116-5","volume":"24","author":"I Ca\u00f1adas","year":"2018","unstructured":"Ca\u00f1adas I, Thummalapalli R, Kim JW, Kitajima S, Jenkins RW, Christensen CL, et al. Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses. Nat Med. 2018;24(8):1143\u201350.","journal-title":"Nat Med."},{"issue":"11","key":"818_CR7","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.1016\/j.celrep.2018.05.050","volume":"23","author":"D Wang","year":"2018","unstructured":"Wang D, Quiros J, Mahuron K, Pai C-C, Ranzani V, Young A, et al. Targeting EZH2 reprograms intratumoral regulatory t cells to enhance cancer immunity. Cell Rep. 2018;23(11):3262\u201374.","journal-title":"Cell Rep"},{"issue":"9","key":"818_CR8","doi-asserted-by":"publisher","first-page":"3813","DOI":"10.1172\/JCI99760","volume":"128","author":"S Goswami","year":"2018","unstructured":"Goswami S, Apostolou I, Zhang J, Skepner J, Anandhan S, Zhang X, et al. Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy. J Clin Invest. 2018;128(9):3813\u20138.","journal-title":"J Clin Invest"},{"issue":"7","key":"818_CR9","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1080\/10428194.2018.1430795","volume":"59","author":"N Gulati","year":"2018","unstructured":"Gulati N, B\u00e9guelin W, Giulino-Roth L. Enhancer of zeste homolog 2 (EZH2) inhibitors. Leuk Lymphoma. 2018;59(7):1574\u201385.","journal-title":"Leuk Lymphoma."},{"issue":"1","key":"818_CR10","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41598-017-01000-2","volume":"7","author":"BD Shields","year":"2017","unstructured":"Shields BD, Mahmoud F, Taylor EM, Byrum SD, Sengupta D, Koss B, et al. Indicators of responsiveness to immune checkpoint inhibitors. Sci Rep. 2017;7(1):807.","journal-title":"Sci Rep."},{"key":"818_CR11","doi-asserted-by":"crossref","unstructured":"Sheahan AV, Morel KL, Burkhart DL, Baca SC, Labb\u00e9 DP, Roehle K, et al. Targeting EZH2 increases therapeutic efficacy of check-point blockade in models of prostate cancer [Internet]. Cancer Biology; 2019 Aug [cited 2020 Jan 13]. Available from: http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/730135","DOI":"10.1101\/730135"},{"issue":"4","key":"818_CR12","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ccell.2019.08.008","volume":"36","author":"ML Burr","year":"2019","unstructured":"Burr ML, Sparbier CE, Chan KL, Chan Y-C, Kersbergen A, Lam EYN, et al. An evolutionarily conserved function of polycomb silences the MHC class i antigen presentation pathway and enables immune evasion in cancer. Cancer Cell. 2019;36(4):385\u2013401.e8.","journal-title":"Cancer Cell"},{"issue":"1","key":"818_CR13","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ccell.2018.06.001","volume":"34","author":"D Zingg","year":"2018","unstructured":"Zingg D, Debbache J, Pe\u00f1a-Hern\u00e1ndez R, Antunes AT, Schaefer SM, Cheng PF, et al. EZH2-Mediated primary cilium deconstruction drives metastatic melanoma formation. Cancer Cell. 2018;34(1):69\u201384.e14.","journal-title":"Cancer Cell"},{"issue":"2","key":"818_CR14","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1097\/DAD.0b013e31828a2d54","volume":"37","author":"P Kampilafkos","year":"2015","unstructured":"Kampilafkos P, Melachrinou M, Kefalopoulou Z, Lakoumentas J, Sotiropoulou-Bonikou G. Epigenetic modifications in cutaneous malignant melanoma: EZH2, H3K4me2, and H3K27me3 immunohistochemical expression is enhanced at the invasion front of the tumor. Am J Dermatopathol. 2015;37(2):138\u201344.","journal-title":"Am J Dermatopathol."},{"issue":"2","key":"818_CR15","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1200\/JCO.2005.01.5180","volume":"24","author":"IM Bachmann","year":"2006","unstructured":"Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA, et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24(2):268\u201373.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"key":"818_CR16","doi-asserted-by":"publisher","first-page":"6051","DOI":"10.1038\/ncomms7051","volume":"6","author":"D Zingg","year":"2015","unstructured":"Zingg D, Debbache J, Schaefer SM, Tuncer E, Frommel SC, Cheng P, et al. The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors. Nat Commun. 2015;6:6051.","journal-title":"Nat Commun."},{"issue":"11","key":"818_CR17","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/nrc1477","volume":"4","author":"MM Mueller","year":"2004","unstructured":"Mueller MM, Fusenig NE. Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer. 2004;4(11):839\u201349.","journal-title":"Nat Rev Cancer."},{"issue":"24","key":"818_CR18","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1093\/jnci\/81.24.1893","volume":"81","author":"WH Clark","year":"1989","unstructured":"Clark WH, Elder DE, Guerry D, Braitman LE, Trock BJ, Schultz D, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst. 1989;81(24):1893\u2013904.","journal-title":"J Natl Cancer Inst."},{"issue":"3","key":"818_CR19","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/pcmr.12757","volume":"32","author":"K N\u011bmejcov\u00e1","year":"2019","unstructured":"N\u011bmejcov\u00e1 K, Tich\u00e1 I, B\u00e1rt\u016f M, Kodet O, D\u016fra M, Jak\u0161a R, et al. Comparison of five different scoring methods in the evaluation of inflammatory infiltration (tumor-infiltrating lymphocytes) in superficial spreading and nodular melanoma. Pigment Cell Melanoma Res. 2019;32(3):412\u201323.","journal-title":"Pigment Cell Melanoma Res."},{"issue":"7420","key":"818_CR20","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/nature11538","volume":"490","author":"J Landsberg","year":"2012","unstructured":"Landsberg J, Kohlmeyer J, Renn M, Bald T, Rogava M, Cron M, et al. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature. 2012;490(7420):412\u20136.","journal-title":"Nature."},{"key":"818_CR21","doi-asserted-by":"publisher","first-page":"8755","DOI":"10.1038\/ncomms9755","volume":"6","author":"S Riesenberg","year":"2015","unstructured":"Riesenberg S, Groetchen A, Siddaway R, Bald T, Reinhardt J, Smorra D, et al. MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment. Nat Commun. 2015;6:8755.","journal-title":"Nat Commun."}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-020-0818-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13148-020-0818-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-020-0818-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T00:59:42Z","timestamp":1612832382000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalepigeneticsjournal.biomedcentral.com\/articles\/10.1186\/s13148-020-0818-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,10]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["818"],"URL":"https:\/\/doi.org\/10.1186\/s13148-020-0818-7","relation":{},"ISSN":["1868-7075","1868-7083"],"issn-type":[{"value":"1868-7075","type":"print"},{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,10]]},"assertion":[{"value":"14 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Specimens and clinical data were acquired with informed consent and Human Ethics Review Committee approval of the University Hospital Bonn (Ethics Review Committee Protocol No. 187\/16).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"F.H., D.N., and JL have received speakers\u2019 honoraria or travel expense reimbursements from the following companies: Roche, BMS, Pierre Fabre, Novartis and MSD. All remaining authors declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24"}}